NICE appraisal of capecitabine (Xeloda) for the treatment of colorectal cancer (adjuvant)

The National Institute for Health and Clinical Excellence (NICE) is currently appraising the use of oxaliplatin and capecitabine for the treatment of colorectal cancer. NICE expects to issue guidance to the NHS in May 2006.

Further information - Colorectal cancer (adjuvant) - oxaliplatin & capecitabine